25 XP   0   0   10

Ionis Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Ionis Pharmaceuticals Inc together

PenkeI guess you are interested in Ionis Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Ionis Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Ionis Pharmaceuticals Inc

I send you an email if I find something interesting about Ionis Pharmaceuticals Inc.

Quick analysis of Ionis Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Ionis Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€2.50
Expected worth in 1 year
€1.29
How sure are you?
55.2%

+ What do you gain per year?

Total Gains per Share
€-1.20
Return On Investment
-3.1%

For what price can you sell your share?

Current Price per Share
€38.94
Expected price per share
€37.71 - €43.71
How sure are you?
50%

1. Valuation of Ionis Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

€38.94

Intrinsic Value Per Share

€-27.51 - €-32.56

Total Value Per Share

€-25.01 - €-30.06

2. Growth of Ionis Pharmaceuticals Inc (5 min.)




Is Ionis Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$386.6m$625.3m-$221.1m-54.7%

How much money is Ionis Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$91.4m-$67.3m-$24m-26.4%
Net Profit Margin-61.2%-47.0%--

How much money comes from the company's main activities?

3. Financial Health of Ionis Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#146 / 1019

Most Revenue
#73 / 1019

Most Profit
#968 / 1019

Most Efficient
#550 / 1019

What can you expect buying and holding a share of Ionis Pharmaceuticals Inc? (5 min.)

Welcome investor! Ionis Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Ionis Pharmaceuticals Inc.

What can you expect buying and holding a share of Ionis Pharmaceuticals Inc?

First you should know what it really means to hold a share of Ionis Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Ionis Pharmaceuticals Inc is €38.94. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ionis Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ionis Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €2.50. Based on the TTM, the Book Value Change Per Share is €-0.30 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.32 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ionis Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.06-0.2%-0.63-1.6%-0.46-1.2%-0.28-0.7%-0.12-0.3%
Usd Book Value Change Per Share0.491.3%-0.32-0.8%-0.34-0.9%-0.27-0.7%0.090.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.491.3%-0.32-0.8%-0.34-0.9%-0.27-0.7%0.090.2%
Usd Price Per Share48.40-42.20-39.16-45.24-44.96-
Price to Earnings Ratio-190.40--57.24--23.73--137.34--167.17-
Price-to-Total Gains Ratio99.05--29.40--156.65-16.84-51.07-
Price to Book Ratio18.24-15.87-9.24-8.91-13.09-
Price-to-Total Gains Ratio99.05--29.40--156.65-16.84-51.07-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share41.358174
Number of shares24
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.32-0.27
Usd Total Gains Per Share-0.32-0.27
Gains per Quarter (24 shares)-7.67-6.59
Gains per Year (24 shares)-30.68-26.36
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-31-410-26-36
20-61-720-53-62
30-92-1030-79-88
40-123-1340-105-114
50-153-1650-132-140
60-184-1960-158-166
70-215-2270-185-192
80-245-2580-211-218
90-276-2890-237-244
100-307-3200-264-270

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%4.016.00.020.0%8.021.00.027.6%8.021.00.027.6%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%8.012.00.040.0%16.013.00.055.2%16.013.00.055.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.029.00.0%0.00.029.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%8.012.00.040.0%16.013.00.055.2%16.013.00.055.2%

Fundamentals of Ionis Pharmaceuticals Inc

About Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Fundamental data was last updated by Penke on 2024-04-18 08:10:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Ionis Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Ionis Pharmaceuticals Inc earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Ionis Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -2.9% means that €-0.03 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ionis Pharmaceuticals Inc:

  • The MRQ is -2.9%. The company is making a loss. -1
  • The TTM is -61.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-2.9%TTM-61.2%+58.4%
TTM-61.2%YOY-47.0%-14.2%
TTM-61.2%5Y-35.1%-26.1%
5Y-35.1%10Y-19.5%-15.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.9%-197.2%+194.3%
TTM-61.2%-210.4%+149.2%
YOY-47.0%-279.3%+232.3%
5Y-35.1%-436.8%+401.7%
10Y-19.5%-599.3%+579.8%
1.1.2. Return on Assets

Shows how efficient Ionis Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Ionis Pharmaceuticals Inc to the Biotechnology industry mean.
  • -0.3% Return on Assets means that Ionis Pharmaceuticals Inc generated €0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ionis Pharmaceuticals Inc:

  • The MRQ is -0.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.3%TTM-3.1%+2.8%
TTM-3.1%YOY-2.7%-0.4%
TTM-3.1%5Y-1.7%-1.4%
5Y-1.7%10Y-0.7%-0.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.3%-13.6%+13.3%
TTM-3.1%-12.9%+9.8%
YOY-2.7%-11.9%+9.2%
5Y-1.7%-14.2%+12.5%
10Y-0.7%-16.2%+15.5%
1.1.3. Return on Equity

Shows how efficient Ionis Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Ionis Pharmaceuticals Inc to the Biotechnology industry mean.
  • -2.4% Return on Equity means Ionis Pharmaceuticals Inc generated €-0.02 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ionis Pharmaceuticals Inc:

  • The MRQ is -2.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -23.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.4%TTM-23.6%+21.2%
TTM-23.6%YOY-10.7%-12.9%
TTM-23.6%5Y-8.9%-14.7%
5Y-8.9%10Y-4.5%-4.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.4%-17.0%+14.6%
TTM-23.6%-16.1%-7.5%
YOY-10.7%-15.4%+4.7%
5Y-8.9%-20.0%+11.1%
10Y-4.5%-21.1%+16.6%

1.2. Operating Efficiency of Ionis Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Ionis Pharmaceuticals Inc is operating .

  • Measures how much profit Ionis Pharmaceuticals Inc makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Ionis Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ionis Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-33.7%+33.7%
TTM-33.7%YOY-69.2%+35.5%
TTM-33.7%5Y-25.6%-8.1%
5Y-25.6%10Y-17.8%-7.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM-33.7%-224.4%+190.7%
YOY-69.2%-288.4%+219.2%
5Y-25.6%-475.2%+449.6%
10Y-17.8%-624.7%+606.9%
1.2.2. Operating Ratio

Measures how efficient Ionis Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.03 means that the operating costs are €1.03 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Ionis Pharmaceuticals Inc:

  • The MRQ is 1.028. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.604. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.028TTM1.604-0.576
TTM1.604YOY1.721-0.117
TTM1.6045Y1.376+0.228
5Y1.37610Y1.379-0.003
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0282.997-1.969
TTM1.6043.247-1.643
YOY1.7213.766-2.045
5Y1.3765.675-4.299
10Y1.3797.857-6.478

1.3. Liquidity of Ionis Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Ionis Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.90 means the company has €5.90 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Ionis Pharmaceuticals Inc:

  • The MRQ is 5.896. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.799. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.896TTM7.799-1.903
TTM7.799YOY8.177-0.378
TTM7.7995Y8.518-0.719
5Y8.51810Y7.865+0.654
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.8963.930+1.966
TTM7.7994.251+3.548
YOY8.1775.436+2.741
5Y8.5186.045+2.473
10Y7.8656.363+1.502
1.3.2. Quick Ratio

Measures if Ionis Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Ionis Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 4.31 means the company can pay off €4.31 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ionis Pharmaceuticals Inc:

  • The MRQ is 4.311. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.950. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.311TTM5.950-1.638
TTM5.950YOY5.956-0.007
TTM5.9505Y6.232-0.283
5Y6.23210Y5.825+0.408
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.3113.629+0.682
TTM5.9504.065+1.885
YOY5.9565.397+0.559
5Y6.2325.993+0.239
10Y5.8256.277-0.452

1.4. Solvency of Ionis Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Ionis Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Ionis Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.87 means that Ionis Pharmaceuticals Inc assets are financed with 87.1% credit (debt) and the remaining percentage (100% - 87.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Ionis Pharmaceuticals Inc:

  • The MRQ is 0.871. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.863. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.871TTM0.863+0.008
TTM0.863YOY0.748+0.114
TTM0.8635Y0.673+0.190
5Y0.67310Y0.685-0.012
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8710.332+0.539
TTM0.8630.334+0.529
YOY0.7480.268+0.480
5Y0.6730.366+0.307
10Y0.6850.390+0.295
1.4.2. Debt to Equity Ratio

Measures if Ionis Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Ionis Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 673.3% means that company has €6.73 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ionis Pharmaceuticals Inc:

  • The MRQ is 6.733. The company is unable to pay all its debts with equity. -1
  • The TTM is 6.475. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ6.733TTM6.475+0.258
TTM6.475YOY2.995+3.480
TTM6.4755Y2.946+3.528
5Y2.94610Y3.086-0.140
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.7330.381+6.352
TTM6.4750.390+6.085
YOY2.9950.334+2.661
5Y2.9460.434+2.512
10Y3.0860.466+2.620

2. Market Valuation of Ionis Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Ionis Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Ionis Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -190.40 means the investor is paying €-190.40 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ionis Pharmaceuticals Inc:

  • The EOD is -162.697. Based on the earnings, the company is expensive. -2
  • The MRQ is -190.398. Based on the earnings, the company is expensive. -2
  • The TTM is -57.242. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-162.697MRQ-190.398+27.701
MRQ-190.398TTM-57.242-133.155
TTM-57.242YOY-23.728-33.514
TTM-57.2425Y-137.345+80.103
5Y-137.34510Y-167.168+29.823
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-162.697-2.315-160.382
MRQ-190.398-2.560-187.838
TTM-57.242-2.664-54.578
YOY-23.728-4.122-19.606
5Y-137.345-6.258-131.087
10Y-167.168-6.108-161.060
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ionis Pharmaceuticals Inc:

  • The EOD is 45.818. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 53.620. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 4.212. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD45.818MRQ53.620-7.801
MRQ53.620TTM4.212+49.408
TTM4.212YOY-39.526+43.737
TTM4.2125Y-18.970+23.182
5Y-18.97010Y-13.083-5.887
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD45.818-3.067+48.885
MRQ53.620-3.251+56.871
TTM4.212-3.545+7.757
YOY-39.526-5.595-33.931
5Y-18.970-8.315-10.655
10Y-13.083-8.708-4.375
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Ionis Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 18.24 means the investor is paying €18.24 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Ionis Pharmaceuticals Inc:

  • The EOD is 15.589. Based on the equity, the company is expensive. -2
  • The MRQ is 18.244. Based on the equity, the company is expensive. -2
  • The TTM is 15.872. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD15.589MRQ18.244-2.654
MRQ18.244TTM15.872+2.372
TTM15.872YOY9.238+6.633
TTM15.8725Y8.906+6.965
5Y8.90610Y13.094-4.188
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD15.5891.905+13.684
MRQ18.2442.111+16.133
TTM15.8722.095+13.777
YOY9.2382.836+6.402
5Y8.9063.443+5.463
10Y13.0943.794+9.300
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Ionis Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.460-0.301+165%-0.321+170%-0.259+156%0.086+434%
Book Value Per Share--2.4982.612-4%4.040-38%5.919-58%5.099-51%
Current Ratio--5.8967.799-24%8.177-28%8.518-31%7.865-25%
Debt To Asset Ratio--0.8710.863+1%0.748+16%0.673+29%0.685+27%
Debt To Equity Ratio--6.7336.475+4%2.995+125%2.946+129%3.086+118%
Dividend Per Share----0%-0%-0%-0%
Eps---0.060-0.591+888%-0.436+628%-0.265+342%-0.117+95%
Free Cash Flow Per Share--0.212-0.542+355%-0.476+324%-0.251+218%-0.251+218%
Free Cash Flow To Equity Per Share--0.476-0.065+114%-0.565+219%-0.296+162%-0.296+162%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---32.561--------
Intrinsic Value_10Y_min---27.509--------
Intrinsic Value_1Y_max---1.611--------
Intrinsic Value_1Y_min---1.581--------
Intrinsic Value_3Y_max---6.099--------
Intrinsic Value_3Y_min---5.797--------
Intrinsic Value_5Y_max---12.105--------
Intrinsic Value_5Y_min---11.127--------
Market Cap5675582880.000-17%6641918640.0005791455720.000+15%5374240620.000+24%6208452192.000+7%6170235012.414+8%
Net Profit Margin---0.029-0.612+2045%-0.470+1548%-0.351+1131%-0.195+583%
Operating Margin----0.3370%-0.6920%-0.2560%-0.1780%
Operating Ratio--1.0281.604-36%1.721-40%1.376-25%1.379-25%
Pb Ratio15.589-17%18.24415.872+15%9.238+97%8.906+105%13.094+39%
Pe Ratio-162.697+15%-190.398-57.242-70%-23.728-88%-137.345-28%-167.168-12%
Price Per Share38.940-17%45.57039.735+15%36.873+24%42.596+7%42.334+8%
Price To Free Cash Flow Ratio45.818-17%53.6204.212+1173%-39.526+174%-18.970+135%-13.083+124%
Price To Total Gains Ratio84.635-17%99.045-29.404+130%-156.652+258%16.843+488%51.071+94%
Quick Ratio--4.3115.950-28%5.956-28%6.232-31%5.825-26%
Return On Assets---0.003-0.031+908%-0.027+776%-0.017+443%-0.007+139%
Return On Equity---0.024-0.236+886%-0.107+349%-0.089+271%-0.045+89%
Total Gains Per Share--0.460-0.301+165%-0.321+170%-0.259+156%0.086+434%
Usd Book Value--386673297.365404273219.188-4%625394705.109-38%916285199.042-58%789335310.863-51%
Usd Book Value Change Per Share--0.489-0.320+165%-0.341+170%-0.275+156%0.091+434%
Usd Book Value Per Share--2.6532.774-4%4.291-38%6.287-58%5.416-51%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.064-0.628+888%-0.463+628%-0.281+342%-0.124+95%
Usd Free Cash Flow--32890919.498-83878244.509+355%-73614831.673+324%-31111527.953+195%-21456226.174+165%
Usd Free Cash Flow Per Share--0.226-0.575+355%-0.505+324%-0.267+218%-0.267+218%
Usd Free Cash Flow To Equity Per Share--0.505-0.069+114%-0.600+219%-0.314+162%-0.314+162%
Usd Market Cap6028036576.848-17%7054381787.5446151105120.212+15%5707980962.502+24%6593997073.123+7%6553406606.685+8%
Usd Price Per Share41.358-17%48.40042.203+15%39.162+24%45.241+7%44.963+8%
Usd Profit---9262695.710-91415246.910+887%-67320788.439+627%-41000853.078+343%-18151403.707+96%
Usd Revenue--324494340.011196921530.915+65%146864425.345+121%201854468.863+61%182921990.815+77%
Usd Total Gains Per Share--0.489-0.320+165%-0.341+170%-0.275+156%0.091+434%
 EOD+3 -5MRQTTM+22 -10YOY+22 -105Y+22 -1010Y+22 -10

3.2. Fundamental Score

Let's check the fundamental score of Ionis Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-162.697
Price to Book Ratio (EOD)Between0-115.589
Net Profit Margin (MRQ)Greater than0-0.029
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.311
Current Ratio (MRQ)Greater than15.896
Debt to Asset Ratio (MRQ)Less than10.871
Debt to Equity Ratio (MRQ)Less than16.733
Return on Equity (MRQ)Greater than0.15-0.024
Return on Assets (MRQ)Greater than0.05-0.003
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Ionis Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose38.940
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets2,990,072
Total Liabilities2,603,386
Total Stockholder Equity386,686
 As reported
Total Liabilities 2,603,386
Total Stockholder Equity+ 386,686
Total Assets = 2,990,072

Assets

Total Assets2,990,072
Total Current Assets2,641,853
Long-term Assets348,219
Total Current Assets
Cash And Cash Equivalents 399,266
Short-term Investments 1,931,935
Inventory 28,425
Other Current Assets 184,449
Total Current Assets  (as reported)2,641,853
Total Current Assets  (calculated)2,544,075
+/- 97,778
Long-term Assets
Property Plant Equipment 242,939
Long-term Assets Other 105,280
Long-term Assets  (as reported)348,219
Long-term Assets  (calculated)348,219
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities448,090
Long-term Liabilities2,155,296
Total Stockholder Equity386,686
Total Current Liabilities
Short Long Term Debt 53,163
Accounts payable 26,027
Total Current Liabilities  (as reported)448,090
Total Current Liabilities  (calculated)79,190
+/- 368,900
Long-term Liabilities
Long term Debt 1,229,501
Capital Lease Obligations Min Short Term Debt170,875
Long-term Liabilities Other 513,736
Long-term Liabilities  (as reported)2,155,296
Long-term Liabilities  (calculated)1,914,112
+/- 241,184
Total Stockholder Equity
Total Stockholder Equity (as reported)386,686
Total Stockholder Equity (calculated)0
+/- 386,686
Other
Capital Stock144
Common Stock Shares Outstanding 144,341
Net Debt 883,398
Net Invested Capital 1,669,350
Net Working Capital 2,193,763
Property Plant and Equipment Gross 339,698



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
912,467
1,083,996
1,090,831
1,252,561
1,322,024
1,299,560
2,247,315
2,247,913
2,667,784
2,835,889
2,877,765
2,894,989
3,233,112
3,090,913
3,078,950
3,095,701
2,390,000
2,248,551
2,497,069
2,414,893
2,612,000
2,519,092
2,456,133
2,421,971
2,534,000
2,885,000
2,971,000
2,933,971
2,990,072
2,990,0722,933,9712,971,0002,885,0002,534,0002,421,9712,456,1332,519,0922,612,0002,414,8932,497,0692,248,5512,390,0003,095,7013,078,9503,090,9133,233,1122,894,9892,877,7652,835,8892,667,7842,247,9132,247,3151,299,5601,322,0241,252,5611,090,8311,083,996912,467
   > Total Current Assets 
797,932
962,372
964,359
1,111,113
1,167,984
1,143,283
2,083,272
2,079,224
2,207,886
2,373,949
2,414,222
2,408,091
2,720,597
2,558,045
2,531,187
2,536,981
2,130,707
1,989,418
2,238,418
2,155,740
2,345,049
2,253,124
2,191,148
2,152,126
2,202,694
2,543,000
2,616,754
2,584,650
2,641,853
2,641,8532,584,6502,616,7542,543,0002,202,6942,152,1262,191,1482,253,1242,345,0492,155,7402,238,4181,989,4182,130,7072,536,9812,531,1872,558,0452,720,5972,408,0912,414,2222,373,9492,207,8862,079,2242,083,2721,143,2831,167,9841,111,113964,359962,372797,932
       Cash And Cash Equivalents 
84,685
114,221
132,991
159,184
129,630
227,505
805,490
479,891
278,820
375,811
272,523
247,939
683,287
486,195
530,181
633,059
1,892,000
414,155
565,119
632,953
2,115,000
542,513
521,917
314,993
1,987,000
309,031
424,790
352,060
399,266
399,266352,060424,790309,0311,987,000314,993521,917542,5132,115,000632,953565,119414,1551,892,000633,059530,181486,195683,287247,939272,523375,811278,820479,891805,490227,505129,630159,184132,991114,22184,685
       Short-term Investments 
582,952
746,060
722,718
851,624
893,085
807,796
1,174,960
1,479,098
1,807,813
1,877,943
1,989,508
1,972,891
1,816,257
1,897,892
1,818,435
1,696,145
1,494,711
1,405,840
1,494,151
1,354,146
1,245,782
1,509,880
1,499,910
1,666,670
1,710,397
2,037,750
1,960,598
1,883,522
1,931,935
1,931,9351,883,5221,960,5982,037,7501,710,3971,666,6701,499,9101,509,8801,245,7821,354,1461,494,1511,405,8401,494,7111,696,1451,818,4351,897,8921,816,2571,972,8911,989,5081,877,9431,807,8131,479,0981,174,960807,796893,085851,624722,718746,060582,952
       Net Receivables 
108,043
69,357
50,615
42,924
62,955
36,858
16,761
14,732
12,759
10,452
31,615
49,077
63,034
28,605
27,834
38,977
76,204
23,397
24,004
9,068
61,896
26,122
6,751
6,645
25,538
14,000
27,956
0
0
0027,95614,00025,5386,6456,75126,12261,8969,06824,00423,39776,20438,97727,83428,60563,03449,07731,61510,45212,75914,73216,76136,85862,95542,92450,61569,357108,043
       Inventory 
7,489
6,801
6,504
8,451
9,982
9,060
9,067
8,378
8,582
11,057
18,505
19,375
18,180
22,885
23,722
22,172
21,965
22,199
24,099
22,930
24,806
24,032
19,811
20,645
22,033
22,200
25,538
25,634
28,425
28,42525,63425,53822,20022,03320,64519,81124,03224,80622,93024,09922,19921,96522,17223,72222,88518,18019,37518,50511,0578,5828,3789,0679,0609,9828,4516,5046,8017,489
       Other Current Assets 
14,763
25,933
51,531
48,930
72,332
62,064
76,994
97,125
99,912
98,686
102,071
118,809
130,621
120,379
126,919
142,334
133,420
120,629
127,784
123,474
113,272
127,111
126,124
135,917
157,715
182,000
169,650
181,075
184,449
184,449181,075169,650182,000157,715135,917126,124127,111113,272123,474127,784120,629133,420142,334126,919120,379130,621118,809102,07198,68699,91297,12576,99462,06472,33248,93051,53125,93314,763
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
461,940
463,543
486,898
512,515
532,868
547,763
558,720
260,000
259,133
258,651
259,153
267,000
265,968
264,985
269,845
331,000
342,000
355,000
349,321
348,219
348,219349,321355,000342,000331,000269,845264,985265,968267,000259,153258,651259,133260,000558,720547,763532,868512,515486,898463,543461,940000000000
       Property Plant Equipment 
92,845
95,439
99,677
116,624
121,907
123,188
127,940
132,003
132,160
146,619
148,249
161,717
166,251
163,952
172,618
181,518
194,177
180,413
179,316
180,144
196,069
177,724
177,015
180,806
256,000
264,000
269,000
245,238
242,939
242,939245,238269,000264,000256,000180,806177,015177,724196,069180,144179,316180,413194,177181,518172,618163,952166,251161,717148,249146,619132,160132,003127,940123,188121,907116,62499,67795,43992,845
       Long Term Investments 
0
0
0
2,000
0
0
0
0
0
0
0
0
10,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000010,000000000002,000000
       Intangible Assets 
20,365
21,175
21,362
21,908
22,004
22,914
23,452
24,027
24,032
25,220
26,056
26,985
25,674
26,750
27,700
28,274
27,937
28,795
29,373
30,038
29,005
29,295
29,054
29,605
0
0
0
0
0
0000029,60529,05429,29529,00530,03829,37328,79527,93728,27427,70026,75025,67426,98526,05625,22024,03224,02723,45222,91422,00421,90821,36221,17520,365
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
461,940
328,000
486,898
358,000
532,868
0
0
79,000
0
0
0
89,000
0
58,916
59,434
75,000
78,000
86,000
104,083
105,280
105,280104,08386,00078,00075,00059,43458,916089,00000079,00000532,868358,000486,898328,000461,940000000000
> Total Liabilities 
812,902
882,190
875,260
854,893
903,305
912,459
1,429,879
1,407,769
1,480,624
1,448,469
1,420,563
1,397,023
1,548,565
1,520,502
1,484,155
1,489,317
1,547,000
1,567,987
1,914,395
1,884,357
1,840,000
1,809,518
1,831,407
1,827,610
1,961,000
2,398,000
2,543,000
2,618,511
2,603,386
2,603,3862,618,5112,543,0002,398,0001,961,0001,827,6101,831,4071,809,5181,840,0001,884,3571,914,3951,567,9871,547,0001,489,3171,484,1551,520,5021,548,5651,397,0231,420,5631,448,4691,480,6241,407,7691,429,879912,459903,305854,893875,260882,190812,902
   > Total Current Liabilities 
133,784
170,580
191,760
177,647
224,741
212,643
248,619
260,238
280,294
252,473
241,213
231,777
273,005
258,025
231,341
244,571
583,250
295,105
293,825
279,778
240,550
228,450
267,811
283,454
311,561
259,000
287,975
404,210
448,090
448,090404,210287,975259,000311,561283,454267,811228,450240,550279,778293,825295,105583,250244,571231,341258,025273,005231,777241,213252,473280,294260,238248,619212,643224,741177,647191,760170,580133,784
       Short-term Debt 
1,185
56
604,133
60
1,621
47
1,164
14,472
13,749
14,500
14,432
2,060
2,026
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000002,0262,06014,43214,50013,74914,4721,164471,62160604,133561,185
       Short Long Term Debt 
1,185
56
604,133
60
1,621
47
1,164
14,472
13,749
14,500
14,432
2,060
2,026
4,150
4,966
5,849
300,462
69,504
69,848
65,045
3,526
0
0
0
7,535
0
0
0
53,163
53,1630007,5350003,52665,04569,84869,504300,4625,8494,9664,1502,0262,06014,43214,50013,74914,4721,164471,62160604,133561,185
       Accounts payable 
81,319
62,374
13,268
23,525
24,886
13,833
13,291
13,576
28,660
13,332
15,628
13,146
16,067
21,174
7,407
16,222
17,199
9,506
14,658
8,357
11,904
16,125
10,351
20,545
17,921
10,499
24,021
5,615
26,027
26,0275,61524,02110,49917,92120,54510,35116,12511,9048,35714,6589,50617,19916,2227,40721,17416,06713,14615,62813,33228,66013,57613,29113,83324,88623,52513,26862,37481,319
       Other Current Liabilities 
51,280
108,150
110,840
104,913
106,465
120,127
160,589
157,145
160,256
163,247
104,000
139,552
150,786
153,757
128,344
114,093
109,700
108,066
103,947
98,375
97,750
92,338
93,407
99,527
104,361
259,000
129,887
9,952
0
09,952129,887259,000104,36199,52793,40792,33897,75098,375103,947108,066109,700114,093128,344153,757150,786139,552104,000163,247160,256157,145160,589120,127106,465104,913110,840108,15051,280
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
1,195,996
1,179,350
1,165,246
1,275,560
1,262,477
1,252,814
1,244,746
1,257,000
1,272,882
1,620,570
1,604,579
1,599,000
1,581,068
1,563,596
1,544,156
1,649,000
1,634,000
1,745,000
2,214,301
2,155,296
2,155,2962,214,3011,745,0001,634,0001,649,0001,544,1561,563,5961,581,0681,599,0001,604,5791,620,5701,272,8821,257,0001,244,7461,252,8141,262,4771,275,5601,165,2461,179,3501,195,996000000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
178,000
177,000
175,000
173,038
170,875
170,875173,038175,000177,000178,000000000000000000000000000
       Other Liabilities 
0
115,759
100,843
79,656
72,708
85,446
556,586
523,384
567,359
542,416
516,584
492,979
490,060
467,842
448,576
429,931
424,046
401,966
379,874
362,887
351,879
333,138
315,196
294,656
287,768
778,000
764,572
0
0
00764,572778,000287,768294,656315,196333,138351,879362,887379,874401,966424,046429,931448,576467,842490,060492,979516,584542,416567,359523,384556,58685,44672,70879,656100,843115,7590
> Total Stockholder Equity
99,565
201,806
215,571
307,968
330,872
301,391
696,255
710,550
1,048,079
1,207,651
1,269,384
1,336,293
1,471,094
1,360,239
1,377,175
1,383,149
843,000
680,564
582,674
530,536
772,000
709,574
624,726
594,361
573,000
487,000
428,000
315,460
386,686
386,686315,460428,000487,000573,000594,361624,726709,574772,000530,536582,674680,564843,0001,383,1491,377,1751,360,2391,471,0941,336,2931,269,3841,207,6511,048,079710,550696,255301,391330,872307,968215,571201,80699,565
   Common Stock
122
124
124
125
125
125
137
138
138
140
140
141
140
139
139
140
140
141
141
141
141
142
142
142
142
487,000
143
0
0
00143487,000142142142142141141141141140140139139140141140140138138137125125125124124122
   Retained Earnings Total Equity00000000000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000
   Capital Surplus 00000000000000000000000000000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 00-50,9130-57,480-63,140-54,007-48,578-32,668-27,437-25,796-24,203-21,071-19,572-16,440-27,235-25,290-25,375-24,252-27,608-32,016-32,532-32,634-33,234-31,759-30,199-30,372-30,460-30,358



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue787,647
Cost of Revenue-9,133
Gross Profit778,514778,514
 
Operating Income (+$)
Gross Profit778,514
Operating Expense-1,141,358
Operating Income-353,711-362,844
 
Operating Expense (+$)
Research Development899,625
Selling General Administrative232,600
Selling And Marketing Expenses-
Operating Expense1,141,3581,132,225
 
Net Interest Income (+$)
Interest Income-
Interest Expense-75,597
Other Finance Cost-5,900
Net Interest Income-81,497
 
Pretax Income (+$)
Operating Income-353,711
Net Interest Income-81,497
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-333,965-454,933
EBIT - interestExpense = -75,597
-366,286
-290,689
Interest Expense75,597
Earnings Before Interest and Taxes (EBIT)--258,368
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-333,965
Tax Provision-32,321
Net Income From Continuing Ops-366,286-366,286
Net Income-366,286
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net101,22281,497
 

Technical Analysis of Ionis Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ionis Pharmaceuticals Inc. The general trend of Ionis Pharmaceuticals Inc is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ionis Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ionis Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 41.30 < 41.82 < 43.71.

The bearish price targets are: 38.72 > 38.54 > 37.71.

Tweet this
Ionis Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ionis Pharmaceuticals Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ionis Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartIonis Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ionis Pharmaceuticals Inc. The current adx is .

Ionis Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartIonis Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc Daily Stochastic Oscillator ChartIonis Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartIonis Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartIonis Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc Daily Williams %R ChartIonis Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc Daily Average True Range (ATR) ChartIonis Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartIonis Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartIonis Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ionis Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-29 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-30 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-18 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-19 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-29 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-09 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-16 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-19 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-22 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-26 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-01 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-16 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-19 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-26 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-28 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-29 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-07 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-13 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-26 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-04 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-05 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-08 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-09 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-10 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-11 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-12 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16 00:00:00MFI LONG ENTRY SHORT CLOSE80 crossover to upside

6.3. Candlestick Patterns

Ionis Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ionis Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose38.940
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Ionis Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Ionis Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ionis Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ionis Pharmaceuticals Inc

I send you an email if I find something interesting about Ionis Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Ionis Pharmaceuticals Inc.

Receive notifications about Ionis Pharmaceuticals Inc in your mailbox!